4,168
Views
39
CrossRef citations to date
0
Altmetric
Review Article

Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine

, , , &
Pages 398-416 | Received 01 Dec 2017, Accepted 20 Jan 2018, Published online: 29 Jan 2018

References

  • Agrawal SS, Saraswati S, Mathur R, Pandey M. (2011). Cytotoxic and antitumor effects of brucine on Ehrlich ascites tumor and human cancer cell line. Life Sci 89:147–58.
  • Allijn IE, Czarny BM, Wang X, et al. (2017). Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. J Control Release 247:127–33.
  • Andresen TL, Jensen SS, Jørgensen K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97.
  • Avramis IA, Kwock R, Avramis VI. (2001). Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 21:2281–6.
  • Barenholz Y. 2007. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: From the bench to approved DOXIL. In: Gregoriadis, G, ed. Liposome technology. 3rd ed., Vol. 2. New York (NY): Informa Healthcare, 1–25.
  • Brown MB, Martin GP, Jones SA, Akomeah FK. (2006). Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 13:175–87.
  • Cai XH, Wang S, Chen BA. (2011). Research advances on the pharmacological effects of tetrandrine. Chin J Nat Med 9:473–80.
  • Camplejohn RS. (1980). A critical review of the use of vincristine (VCR) as a tumour cell synchronizing agent in cancer therapy. Cell Tissue Kinet 13:327–35.
  • Cao J, Sun J, Wang X, et al. (2009). N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm 35:1339–47.
  • Chai NL, Fu Q, Shi H, et al. (2012). Oxymatrine liposome attenuates hepatic fibrosis via targeting hepatic stellate cells. World J Gastroenterol 18:4199–206.
  • Chen J, He H, Li S, Shen Q. (2011a). An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. J Chromatogr B Analyt Technol Biomed Life Sci 879:1967–72.
  • Chen J, Li S, Shen Q, et al. (2011b). Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Dev Ind Pharm 37:1339–46.
  • Chen J, Yan GJ, Hu RR, et al. (2012). Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. Int J Nanomedicine 7:3567–77.
  • Chen KJ, Chen K. (1992). Ischemic stroke treated with Ligusticum chuanxiong. Chin Med J 105:870–3.
  • Chen WL, Yuan ZQ, Liu Y, et al. (2016). Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro. Int J Nanomedicine 11:325–36.
  • Chen Y, Liang X, Ma P, et al. (2015). Phytantriol-based in situ liquid crystals with long-term release for intra-articular administration. AAPS PharmSciTech 16:846–54.
  • Chourpa I, Millot JM, Sockalingum GD, et al. (1998). Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim Biophys Acta 1379:353–66.
  • Coburn JM, Na E, Kaplan DL. (2015). Modulation of vincristine and doxorubicin binding and release from silk films. J Control Release 220:229–38.
  • Cui J, Li C, Wang C, et al. (2011). Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?. J Pharm Sci 100:2835–48.
  • Deitcher OR, Glaspy J, Gonzalez R, et al. (2014). High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk 14:197–202.
  • Douer D. (2016). Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. Oncologist 21:840–7.
  • Fan C, Li X, Zhou Y, et al. (2013). Enhanced topical delivery of tetrandrine by ethosomes for treatment of arthritis. Biomed Res Int 2013:161943.
  • Fang YP, Tsai YH, Wu PC, Huang YB. (2008). Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm 356:144–52.
  • Gómez-Hens A, Fernández-Romero JM. (2006). Analytical methods for the control of liposomal delivery systems. Trac-Trend Anal Chem 25:167–78.
  • Gray PH, Lachance RA. (1956). Assimilation of berberine by bacteria. Nature 177:1182–3.
  • Guo T, Zhang Y, Zhao J, et al. (2015). Nanostructured lipid carriers for percutaneous administration of alkaloids isolated from Aconitum sinomontanum. J Nanobiotechnol 13:47.
  • Harris JC, Coburn JM, Kajdacsy-Balla A, et al. (2016). Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth. J Pediatr Surg 51:2058–62.
  • Huang A, Makhlof A, Ping Q, et al. (2011). N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin. Drug Deliv 18:562–9.
  • Joguparthi V, Xiang TX, Anderson BD. (2008). Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67. J Pharm Sci 97:400–20.
  • Kaplan LD, Deitcher SR, Silverman JA, Morgan G. (2014). Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk 14:37–42.
  • Kono K, Henmi A, Yamashita H, et al. (1999). Improvement of temperature-sensitivity of poly(N-isopropylacrylamide)-modified liposomes. J Control Release 59:63–75.
  • Leiva A, Quina FH, Araneda E, et al. (2007). New three-arm amphiphilic and biodegradable block copolymers composed of poly(epsilon-caprolactone) and poly(N-vinyl-2-pyrrolidone). Synthesis, characterization and self-assembly in aqueous solution. J Colloid Interface Sci 310:136–43.
  • Li J, Chen J, Cai BC, Yang T. (2013). Preparation, characterization and tissue distribution of brucine stealth liposomes with different lipid composition. Pharm Dev Technol 18:772–8.
  • Li JS, Wang HF, Bai YP, et al. (2012). Ligustrazine injection for chronic pulmonary heart disease: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2012:792726.
  • Li K, Wang S. (2016). Preparation, pharmacokinetic profile, and tissue distribution studies of a liposome-based formulation of SN-38 using an UPLC-MS/MS method. AAPS PharmSciTech 17:1450–6.
  • Li M, Li Z, Yang Y, et al. (2016). Erratum to: thermo-sensitive liposome co-loaded of vincristine and doxorubicin based on their similar physicochemical properties had synergism on tumor treatment. Pharm Res 33:2307.
  • Li ZW, Ma XY, Wang MN, et al. (2004). Investigation of pharmacokinetics of oxymatrine soft capsule in healthy volunteers. Northwest Pharm J 19:149–151.
  • Liang GW, Lu WL, Wu JW, et al. (2008). Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol 22:429–437.
  • Lin YC, Kuo JY, Hsu CC, et al. (2013). Optimizing manufacture of liposomal berberine with evaluation of its antihepatoma effects in a murine xenograft model. Int J Pharm 441:381–388.
  • Liu CF, Lin CC, Ng LT, Lin SC. (2002). Hepatoprotective and therapeutic effects of tetramethylpyrazine on acute econazole-induced liver injury. Planta Med 68:510–514.
  • Liu JH, Li WD, Teng HL, Lin ZB. (2005). Immunopharmacological action of sinomenine, an alkaloid isolated from Sinomenium acutum, and its mechanism of action in treating rheumatoid arthritis. Acta Pharm Sin 40:127–131.
  • Liu X, Liu H, Liu J, et al. (2011a). Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo. Int J Nanomedicine 6:241–247.
  • Liu X, Liu H, Zeng Z, et al. (2011b). Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect. Int J Nanomedicine 6:1391–1398.
  • Liu XY, Fang H, Yang ZG, et al. (2008). Matrine inhibits invasiveness and metastasis of human malignant melanoma cell line A375 in vitro. Int J Dermatol 47:448–456.
  • Liu XY, Ruan LM, Mao WW, et al. (2010). Preparation of RGD-modified long circulating liposome loading matrine, and its in vitro anti-cancer effects. Int J Med Sci 7:197–208.
  • Liu Y, Feng N. (2015). Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM). Adv Colloid Interface Sci 221:60–76.
  • Liu Y, He M, Niu M, et al. (2015). Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency. Int J Nanomedicine 10:3081–3095.
  • Liu Z, Liu Q, Xu B, et al. (2009). Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat Res 662:75–83.
  • Ma X, Zhou J, Zhang CX, et al. (2013). Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 34:4452–4465.
  • Ma Y, Li WZ, Guan SX, et al. (2009). Evaluation of tetrandrine sustained release calcium alginate gel beads in vitro and in vivo. Yakugaku Zasshi 129:851–854.
  • Malone MH, St John-Allan KM, Bejar E. (1992). Brucine lethality in mice. J Ethnopharmacol 35:295–297.
  • Mayer LD, Masin D, Nayar R, et al. (1995). Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71:482–488.
  • Mei D, Mao S, Sun W, et al. (2008). Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur J Pharm Biopharm 70:874–881.
  • Mishra D, Mishra PK, Dabadghao S, et al. (2010). Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine 6:110–118.
  • Moghimi HR, Williams AC, Barry BW. (1996). A lamellar matrix model for stratum corneum intercellular lipids. II. Effect of geometry of the stratum corneum on permeation of model drugs 5-fluorouracil and oestradiol. Int J Pharm 131:117–129.
  • Nakamura K, Yoshino K, Yamashita K, Kasukawa H. (2012). Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method. Int J Pharm 430:381–387.
  • Narishetty ST, Panchagnula R. (2004). Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. J Control Release 95:367–379.
  • Nie S, Hsiao WL, Pan W, Yang Z. (2011). Thermoreversible pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine 6:151–166.
  • O'Brien S, Schiller G, Lister J, et al. (2013). High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 31:676–683.
  • Ozeki T, Kaneko D, Hashizawa K, et al. (2012). Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel. Int J Pharm 427: 299–304.
  • Pal A, Khan S, Wang YF, et al. (2005). Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 25:331–341.
  • Pereira GC, Branco AF, Matos JAC, et al. (2007). Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J Pharmacol Exp Ther 323:636–649.
  • Philippe G, Angenot L, Tits M, Frédérich M. (2004). About the toxicity of some Strychnos species and their alkaloids. Toxicon 44:405–416.
  • Ping YH, Lee HC, Lee JY, et al. (2006). Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol Rep 15: 1273–1279.
  • Pinhassi RI, Assaraf YG, Farber S, et al. (2010). Arabinogalactan − folic acid − drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules 11:294–303.
  • Pirillo A, Catapano AL. (2015). Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis 243:449–461.
  • Rao S, Sikdar SK. (2000). Modification of alpha subunit of RIIA sodium channels by aconitine. Pflugers Arch 439:349–355.
  • Said R, Tsimberidou AM. (2014). Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol 10:483–494.
  • Senior J, Gregoriadis G. (1982). Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett 145:109–114.
  • Sethi VS, Jackson DV, Jr., White DR, et al. (1981). Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41:3551–3555.
  • Shan S, Flowers C, Peltz CD, et al. (2006). Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. Cancer Chemother Pharmacol 58:245–255.
  • Shi D, Greever R, Chen Y. (2010a). Preparation and characterization of novel sinomenine microcapsules for oral controlled drug delivery. Drug Dev Ind Pharm 36:482–489.
  • Shi J, Cong WJ, Wang YM, et al. (2012a). Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease. Drug Dev Ind Pharm 38:752–761.
  • Shi J, Wang YM, Luo GA. (2012b). Ligustrazine phosphate ethosomes for treatment of Alzheimer's disease, in vitro and in animal model studies. AAPS PharmSciTech 13:485–492.
  • Shi K, Tian Y, Jiang Y, et al. (2010b). Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation. Pharm Dev Technol 15:644–652.
  • Shukla SK, Mishra AK, Arotiba OA, Mamba BB. (2013). Chitosan-based nanomaterials: a state-of-the-art review. Int J Biol Macromol 59:46–58.
  • Silverman JA, Deitcher SR. (2013). Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71:555–564.
  • Silverman JA, Reynolds L, Deitcher SR. (2013). Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol 53:1139–1145.
  • Song J, Bi H, Xie X, et al. (2013). Preparation and evaluation of sinomenine hydrochloride in situ gel for uveitis treatment. Int Immunopharmacol 17:99–107.
  • Song XL, Liu S, Jiang Y, et al. (2017). Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG2000-transferrin in treatment of brain glioma. Eur J Pharm Sci 96:129–140.
  • Sun JE, Stewart B, Litan A, et al. (2016). Sustained release of active chemotherapeutics from injectable-solid β-hairpin peptide hydrogel. Biomater Sci 4:839–848.
  • Sun Y, Wang L, Sun S, et al. (2008). The effect of 10-hydroxycamptothecine in preventing fibroblast proliferation and epidural scar adhesion after laminectomy in rats. Eur J Pharmacol 593:44–48.
  • Tenjarla S. (1999). Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 16:461–521.
  • Thakur V, Kush P, Pandey RS, et al. (2016). Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: in vitro and in vivo study. Mater Sci Eng C Mater Biol Appl 61:113–122.
  • Thanou M, Verhoef JC, Junginger HE. (2001). Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 50:S91–S101.
  • Thomas DA, Kantarjian HM, Stock W, et al. (2009). Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115:5490–5498.
  • Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–243.
  • Van der Merwe SM, Verhoef JC, Verheijden JH, et al. (2004). Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm 58:225–235.
  • Vuddanda PR, Mishra A, Singh SK, Singh S. (2015). Development of polymeric nanoparticles with highly entrapped herbal hydrophilic drug using nanoprecipitation technique: an approach of quality by design. Pharm Dev Technol 20:579–587.
  • Wang J, Dong C, Song Z, et al. (2017). Monocyclic monoterpenes as penetration enhancers of ligustrazine hydrochloride for dermal delivery. Pharm Dev Technol 22:571–577.
  • Wang Q, Li XK. (2011). Immunosuppressive and anti-inflammatory activities of sinomenine. Int Immunopharmacol 11:373–376.
  • Wang XW, Xie H. (1999). Alkaloids of Chinese aconitum plants. Drugs Fut 24:877–882.
  • Wang YP, Zhao W, Xue R, et al. (2011). Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance. Antiviral Res 89:227–231.
  • Webb MS, Saxon D, Wong FM, et al. (1998). Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372:272–282.
  • Wei L, Marasini N, Li G, et al. (2012). Development of ligustrazine-loaded lipid emulsion: formulation optimization, characterization and biodistribution. Int J Pharm 437:203–212.
  • Wissing S, Müller R. (2002). The influence of the crystallinity of lipid nanoparticles on their occlusive properties. Int J Pharm 242:377–379.
  • Wu XN, Wang GJ. (2004). Experimental studies of oxymatrine and its mechanisms of action in hepatitis B and C viral infections. Chin J Dig Dis 5:12–16.
  • Xiong F, Tian J, Hu K, et al. (2016). Superparamagnetic anisotropic nano-assemblies with longer blood circulation in vivo: a highly efficient drug delivery carrier for leukemia therapy. Nanoscale 8:17085–17089.
  • Xu H, Hou Z, Zhang H, et al. (2014). An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion. Int J Nanomedicine 9:231–242.
  • Xu H, Shi DZ. (2003). The clinical application and pharmacological effect of Ligustrazine. Chin J Integr Tradit West Med 23:376–377.
  • Xu M, Liu L, Qi C, et al. (2008). Sinomenine versus NSAIDs for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Planta Med 74:1423–1429.
  • Xu X, Xiang Q, He Z, et al. (2010). Crystalline drug aconitine-loaded poly(d,l-lactide-coglycolide) nanoparticles: preparation and in vitro release. Yakugaku Zasshi 130:409–418.
  • Yan Z, Zhu ZL, Qian ZZ, et al. (2012). Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacol Sin 33:852–858.
  • Yang J, Ni B, Liu J, et al. (2011). Application of liposome-encapsulated hydroxycamptothecin in the prevention of epidural scar formation in New Zealand white rabbits. Spine J 11:218–223.
  • Yang SJ, Lin FH, Tsai KC, et al. (2010). Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconjug Chem 21:679–689.
  • Yang YH, Wang QQ, Li J, et al. (2016). Ligustrazine-loaded stealth liposomes: cellular uptake in murine phagocyte cell model and pharmacokinetics in rats. Lat Am J Pharm 35:32–37.
  • Zamboni WC, Jung LL, Strychor S, et al. (2008). Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice. Invest New Drugs 26:399–406.
  • Zeng F, Ju RJ, Liu L, et al. (2015). Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. Oncotarget 6: 36625–36642.
  • Zhang CF, Yang ZL, Luo JB, et al. (2007). Effects of cinnamene enhancers on transdermal delivery of ligustrazine hydrochloride. Eur J Pharm Biopharm 67:413–419.
  • Zhang J, Chen Y, Li X, et al. (2016). The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate. Int J Nanomedicine 11:4187–4197.
  • Zhang L, Han L, Sun X, et al. (2012). The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia 83:678–689.
  • Zhang T, Zheng Y, Peng Q, et al. (2013). A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. Int J Nanomedicine 8:1185–1196.
  • Zhang WJ, Wang JY, Li H, et al. (2015a). Novel application of natural anisole compounds as enhancers for transdermal delivery of ligustrazine. Am J Chin Med 43:1231–1246.
  • Zhang X, Wei J, Ma P, et al. (2015b). Preparation and evaluation of a novel biodegradable long‐acting intravitreal implant containing ligustrazine for the treatment of proliferative vitreoretinopathy. J Pharm Pharmacol 67:160–169.
  • Zhang YJ, Yang SH, Li MH, et al. (2014a). Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy. Clin Exp Pharmacol Physiol 41:995–1002.
  • Zhang YT, Han MQ, Shen LN, et al. (2015c). Solid lipid nanoparticles formulated for transdermal aconitine administration and evaluated in vitro and in vivo. J Biomed Nanotechnol 11:351–361.
  • Zhang YT, Wu ZH, Zhang K, et al. (2014b). An in vitro and in vivo comparison of solid and liquid-oil cores in transdermal aconitine nanocarriers . J Pharm Sci 103:3602–3610.
  • Zhang YT, Zhao JH, Zhang SJ, et al. (2011). Enhanced transdermal delivery of evodiamine and rutaecarpine using microemulsion. Int J Nanomedicine 6:2469–2482.
  • Zhao L, Fang L, Li Y, et al. (2011). Effect of (E)-2-isopropyl-5-methylcyclohexyl octadec-9-enoate on transdermal delivery of aconitum alkaloids. Drug Dev Ind Pharm 37:290–299.
  • Zhao YQ, Wang LP, Ma C, et al. (2013). Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers. Int J Nanomedicine 8:4169–4181.
  • Zhou WT, An XQ, Wang JZ, et al. (2012). Characteristics, phase behavior and control release for copolymer–liposome with both pH and temperature sensitivities. Colloids Surf A 395: 225–232.
  • Zhou Y, Liu SQ, Peng H, et al. (2015). In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis. Int Immunopharmacol 28:34–43.
  • Zhu G, Oto E, Vaage J, et al. (1996). The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol 39:138–142.
  • Zucker D, Andriyanov AV, Steiner A, et al. (2012). Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 160:281–289.